Polianta Ltd’s NovoCure NVCR Stock Holding History

Polianta Ltd’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,300	Closed	-$799K	–	90
2023 Q1	$799K	Buy	+13,300	New	+$1.06M	0.37%	69
2020 Q2	–	Sell	-13,000	Closed	-$875K	–	90
2020 Q1	$875K	Sell	13,000 -1,200	-8%	-$94.8K	0.6%	20
2019 Q4	$1.2M	Buy	14,200 +1,900	+15%	+$153K	0.73%	21
2019 Q3	$919K	Buy	+12,300	New	+$984K	0.58%	59

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Polianta Ltd's NVCR Position: Q2 2023 in Review

Polianta Ltd sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 13,300 shares — an estimated $799K sold.

Polianta Ltd first reported a position in NVCR in Q3 2019 and held it in 4 quarters. The position peaked at $1.2M in Q4 2019. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Polianta Ltd reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Polianta Ltd sold 13,300 NovoCure shares in Q2 2023, an estimated $799K.
Polianta Ltd first reported a position in NovoCure in Q3 2019 and held it in 4 quarters.
Polianta Ltd's NovoCure position peaked at $1.2M in Q4 2019.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Polianta Ltd's 13F filing for Q2 2023, filed 19 Jul 2023.